Fibrinogen and tumors

Abstract

Elevated plasma fibrinogen (Fg) levels consistently correlate with an unfavorable prognosis in various tumor patient cohorts. Within the tumor microenvironment, aberrant deposition and expression of Fg have been consistently observed, interacting with multiple cellular receptors and thereby accentuating its role as a regulator of inflammatory processes. Specifically, Fg serves to stimulate and recruit immune cells and pro-inflammatory cytokines, thereby contributing to the promotion of tumor progression. Additionally, Fg and its fragments exhibit dichotomous effects on tumor angiogenesis. Notably, Fg also facilitates tumor migration through both platelet-dependent and platelet-independent mechanisms. Recent studies have illuminated several tumor-related signaling pathways influenced by Fg. This review provides a comprehensive summary of the intricate involvement of Fg in tumor biology, elucidating its multifaceted role and the underlying mechanisms.

1 Introduction

Fibrinogen (Fg), a 340 kDa dimeric glycoprotein, is synthesized by hepatocytes and composed of three polypeptide chains: fibrinogen Aα (FGA, 52.0 kDa), Bβ (FGB, 52.0 kDa), and γ (FGG, 46.5 kDa (1). Each Fg molecule comprises two outer D domains connected by a central E domain, with the E-region encompassing the N-terminus of Aα, Bβ, and γ chains, while the D-region consists of the C-terminus of the Bβ and γ chains (2).

Traditionally recognized as a coagulation factor, Fg undergoes transformation into a fibrin polymer during the clotting cascade. In its role as an acute-phase reaction protein, Fg actively engages in inflammatory processes and interacts with the activation and migration of leukocytes (3). Noteworthy, previous research has consistently reported elevated plasma Fg levels across various tumor types, underscoring its significant involvement in tumorigenesis (4).

Moreover, Fg deposition has been observed in the tumor extracellular matrix (5) and the walls of angiogenic blood vessels (6), implying associations between Fg and tumor angiogenesis and metastasis. These interactions are mediated by binding sites on Fg, which engage with diverse molecules, including various plasma proteins and cellular receptors (7). Furthermore, multiple pathways have been identified linking Fg to tumor progression (8). This comprehensive review provides an in-depth overview of the pivotal role played by Fg in tumor biology, emphasizing its crucial contributions to angiogenesis, metastasis, and inflammation within the tumor microenvironment.

2 The role and mechanism of Fg in tumors

2.1 Plasma Fg levels in tumor patient cohorts

Elevated plasma fibrinogen(Fg) levels consistently manifest in diverse tumor patient cohorts (9). In lung, rectal, and stomach cancers, heightened Fg levels correlate with poorer survival (10–12) are recognized as an independent prognostic marker (4). In lymphoma and leukemia, multivariate analysis underscores plasma Fg as a biomarker and a robust predictor.

Table 1 furnishes a comprehensive overview delineating the multifaceted roles and associations of pre-treatment plasma Fg levels within diverse medical contexts. The presented findings underscore the versatile nature of Fg, positioning it as both a prognostic marker and a predictor across varying conditions, including considerations of tumor-node-metastasis (TNM) stage and responses to surgery or chemoradiotherapy.

Notably, although the prognosis of Fg has been demonstrated in most tumors, the prognosis of Fg in certain tumors remains controversial. In patients with relapsed and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), Fg levels may serve as a predictive indicator for survival (51). However, insights from Nenclares’ research on oral squamous cell carcinoma (OSCC) patients suggest that Fg levels lack predictive value in this context (52). Additionally, it is noteworthy that decreased plasma Fg levels are indicative of poor prognosis in angiosarcoma of the head and neck (ASHN) (53) and acute promyelocytic leukemia (APL) (54), as reported in the literature.

Elevated Fg levels in patients undergoing treatment for various tumors often correlate with poor prognosis, offering clinicians valuable insights for treatment planning and patient management. In surgical settings, heightened preoperative Fg levels typically signal a bleak prognosis post-surgery, warranting vigilant monitoring. Regarding chemotherapy, patients with hepatocellular carcinoma and elevated preoperative plasma Fg levels tend to exhibit poor responses to transarterial chemoembolization (TACE) (55). Similarly, in rectal cancer patients undergoing chemoradiotherapy (CRT) with radiotherapy, those with lower pre-treatment Fg levels (≤270 mg/mL) are more than twice as likely to achieve complete remission compared to counterparts with higher pre-treatment Fg levels (>270 mg/mL) (11). Moreover, in esophageal squamous cell carcinoma (ESCC), patients with elevated Fg levels demonstrate reduced responsiveness to navumab (20). These findings underscore the importance of tailoring chemotherapy regimens to individual cancer patients with elevated Fg levels to optimize treatment efficacy. Therefore, prioritizing the assessment of elevated Fg levels before treatment is imperative, enabling clinicians to customize treatment strategies and accurately evaluate post-treatment prognosis for cancer patients.

2.2 Fg in tumor extracellular matrix

Research has unveiled the presence of Fg in the tumor stroma, predominantly composed of connective tissues, inflammatory cells, and newly formed blood vessels (56). Elevated Fg expression has been detected in various original tumor biopsy samples, encompassing patients with breast cancer (57), uterine cervix carcinoma (58) and HCC (5), among others. Mechanistic insights into Fg expression in the tumor mesenchyme vary across different tumor settings. In cases of central nervous system lymphoma, disruption of the blood-brain barrier contributes to enhanced Fg deposition within the tumor stroma (59). In breast cancer, the binding interactions between Fg β15-42 and VE-cadherin improve endothelial barrier permeability (60). Increased vascular permeability within tumors results in the leakage of Fg from plasma into the tumor stroma (61). Notably, Fg deposition in acute promyelocytic leukemia is mediated by Fg binding to CD44 on APL blasts and NB4 cells (62).

Furthermore, tumor cells, including lung adenocarcinoma A549 cells (63), hepatocellular carcinoma HepG2 cells (64), human breast carcinoma MCF-7 cells (57) and uterine cervix carcinoma ME-180 cell (58), have been identified as capable of synthesizing and secreting Fg. This synthesis is attributed to elevated transcription of fibrinogen Aα (FGA), fibrinogen Bβ (FGB), and fibrinogen γ (FGG) genes.

Table 2 provides a comprehensive summary of diverse observations related to Fg expression across different pathological contexts.

2.3 Pro-inflammatory role of Fg in tumors

Inflammation serves as a driving force across all stages of carcinogenesis, fostering cancer growth. The creation of an inflammatory tumor microenvironment (TME) results from intricately coordinated interactions involving cancer cells, stromal cells, and inflammatory cells (76). Additionally, tumor cells actively contribute to crucial stages of leukocyte recruitment and trafficking (77). These processes encompass chemokine-induced migration, coupled with the activation of leukocyte integrins and selectin adhesion molecules, facilitating the interaction of tumor cells with vascular endothelium and subsequent extravasation.

Vascular and leukocyte responses play pivotal roles in the pathogenesis of inflammation. Elevated vascular permeability is among the initial responses to inflammation. Fibrinogen (Fg) plays a role in facilitating the subsequent transendothelial migration of leukocytes by binding to VE-cadherin in vascular endothelial cells (60). Additionally, Fg activates AKT signaling and induces microfilament depolymerization, thereby enhancing endothelial barrier permeability (78).

Recent evidence has highlighted the association between circulating Fg and DNA methylation in peripheral blood leukocytes (79), underscoring Fg’s role in leukocyte migration and recruitment. Acting as a bridging molecule, Fg links leukocyte integrin αMβ2 (Mac-1) to intercellular adhesion molecule-1 (ICAM-1) on endothelial cells (ECs) (80), facilitating leukocyte adhesion and transvascular migration across the vascular endothelium. Moreover, at sites of inflammation, Fg interacts with immune cells, hastening their recruitment to participate in the inflammatory cascade (81). (Figure 1) A reciprocal relationship exists between leukocytes and Fg, wherein during inflammation, reactive oxygen species (ROS) from neutrophils and monocytes, along with nitric oxide from lymphocytes and monocytes, cleave Fg (82). Subsequently, protease-cleaved Fg binds to macrophage toll-like receptors, amplifying the inflammatory response through an allergic cascade (83). This establishes a positive feedback loop between Fg and immune cells, intensifying the inflammatory milieu.

Figure 1

Moreover, inflammatory mediators play crucial regulatory roles in both vascular and leukocyte responses. Fg has been implicated in promoting inflammatory responses by enhancing the secretion of inflammatory factors, either independently or in response to various environmental cues.

Studies have demonstrated that Fg upregulates the secretion of several cytokines, including IL-6, IL-17, IL-23, TNF-α, macrophage inflammatory protein-1 α (MIP-1α), MIP-1β, MIP-2, and monocyte chemotactic protein-1 (MCP-1) (84–86). The molecular mechanisms underlying Fg-mediated promotion of inflammatory factors have also been elucidated. Fg participates in the inflammatory process by activating the NF-κB pathway and inducing the expression of interleukin-6 (IL-6), interleukin-8, monocyte chemotactic protein-1 (MCP-1), and C-C chemokine ligand-2 (CCL2) (87, 88).

Furthermore, Fg has been found to stimulate cytokine secretion under various conditions. Specific chemical modifications, such as D-ibose glycosylation, can enhance Fg’s involvement in specific inflammatory responses, resulting in increased expression of inflammation-associated cytokine genes, including TNF-α, IL-6, IL-1β, and IFN-γ (89). Additionally, specific enzymatic structures, such as atypical cross-linking mediated by the glutamine transferase transglutaminase-2 (TG2), enhance the secretion of pro-inflammatory cytokines (e.g. TNF-α) in myeloid macrophages, while simultaneously reducing the expression of IL-10 and inhibiting the phosphorylation of STAT3 (90).

In the specific context of a tumor, the role of Fg and immune cells undergo alterations. Typically, during inflammation, Fg activates macrophages, polarizing them into pro-inflammatory M1 macrophages via integrin α1β3. This activation leads to the expression of M1 macrophage-specific markers such as inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) (91). However, within the tumor microenvironment, Fg becomes associated with increased infiltration of tumor-associated macrophages (TAMs) exhibiting an M2 phenotype. These M2 TAMs promote tumor growth, induce angiogenesis, and suppress immune responses (20).

Importantly, within the specific context of a tumor, the interplay between Fg and immune cells may contribute to tumor development. Distinct interactions occur between Fg γ^390-396A and leukocyte integrin αMβ2 (Mac-1) (92), typically mediated by Fg binding to CD11b (93). These interactions lead to the activation of downstream proteins, including focal adhesion kinase (FAK) phosphorylation and mitogen-activated protein kinase (MAPK) activation. Consequently, this triggers various processes such as leukocyte degranulation, recruitment (94), phagocytosis, and induction of inflammatory responses (95). Specifically, within the tumor microenvironment, Fg γ^390-396A’s interaction with leukocyte integrin αMβ2 not only enhances the secretion of pro-inflammatory cytokines like IL-6, IL-1β, IFN-γ, and TNF-α but also promotes tumor cell proliferation (96). This dual role underscores Fg’s contribution to inflammation and tumor development within tumors.

2.4 Fg and angiogenesis

The relationship between Fibrinogen (Fg) and angiogenesis remains a subject of ongoing debate, with recent research shedding light on its dual role—both pro- and anti-angiogenic—in specific tissue contexts, particularly within the spectrum of various diseases.

The role of Fg in angiogenesis varies depending on the environmental context. In skin wound models, a distinctive pattern emerges as Fg infiltrates the lesion during the inflammatory phase, coinciding with a decline in vascular integrity. Notably, this Fg deposition correlates with heightened re-epithelialization and accelerated angiogenesis, emphasizing its context-dependent pro-angiogenic effects (97). Contrasting observations arise in a colon cancer MC38 model, where mice deficient in Fg exhibit lower vascular density compared to control mice. This effect is found to be time-dependent (98), further illustrating the intricate dynamics involved.

Fg demonstrates a pro-angiogenic effect under certain conditions. Recent insights highlight the direct interaction of circulating Fg with various growth factors, encompassing members of the vascular endothelial growth factor (VEGF) family and fibroblast growth factor (FGF). This interaction stimulates endothelial cell proliferation, fostering angiogenesis, and fueling tumor cell growth (99, 100). Mechanistically, tumor-derived Fg amplifies the impact of FGF-2 on endothelial proliferation through coordinated effects involving integrin αvβ3 and FGFR1 (FGF receptor 1) (101).

Moreover, Fg can promote angiogenesis through alternative mechanisms. Fg collaborates with immune cells to orchestrate a dual-promotional role in immune cell recruitment and angiogenesis (102). This multifaceted engagement includes the inhibition of tumor angiogenesis inhibitors, such as Endostatin, by Fg, thereby promoting angiogenic aggregation (103).

Additionally, specific fragments of Fg have been implicated in promoting angiogenesis. Fg α component enhances mesenchymal cell-endothelial cell interactions, actively participating in angiogenesis through the VEGA-VEGFR-FAK signaling axis (104).Exploring the intricate landscape of Fg binding sites involved in tumor angiogenesis reveals a nuanced interplay of molecular interactions that influence endothelial cell behavior. One reported interaction spotlights arginine-glycine-aspartic acid (RGD) site in at α252-254 or α572–574 region, showcasing its direct engagement with integrin αvβ3. This interaction holds the potential to function as a survival signal for endothelial cells, orchestrating pivotal roles in the angiogenic process (105).

Contrastingly, some studies challenge the notion of Fg’s indispensability for angiogenesis, suggesting potential anti-angiogenic roles. Integrin αvβ3 serves as a pivotal receptor that mediates the interaction between Fg and angiogenesis, with different fragments of Fg exhibiting distinct effects upon binding to this receptor. Interestingly, while certain Fg fragments have been associated with pro-angiogenic effects through integrin αvβ3 binding, others have been linked to the inhibition of tumor angiogenesis. An intriguing find lies in the β43-63 region, identified as a novel anti-tumor peptide due to its anti-angiogenic activity mediated by integrin αvβ3 (106). Additionally, the γC component and its truncation mutant (γC399tr) emerge as determinants in the binding of Fg to endothelial cells via integrin αvβ3. This interaction, in turn, contributes to endothelial cell apoptosis and a reduction in tube formation (107) (Figure 2).

Figure 2

Moreover, certain fragments of Fg have been reported to be linked to the inhibition of tumor angiogenesis. A key functional fragment, Fg α1-24, known as alphastatin, exhibits inhibitory effects on bFGF- and VEGF-induced migration, proliferation, and tubule formation of microvascular endothelial cells (108). This inhibition is mediated through the suppression of the JNK and ERK kinase pathways (109). Alphastatin’s localized effects extend to cellular necrosis, thrombosis, and vessel rupture (110), collectively acting as a potent inhibitor of angiogenesis and tumor growth (111). Notably, the down-regulation of Fg E-fragment in tumors (112) hinted at its detrimental impact on tumor growth. Subsequent investigations propose that the Fg E fragment might be linked to the inhibition of tumor angiogenesis.

Despite numerous studies reporting either promotion or inhibition of angiogenesis by Fg and its fragments, there are also studies indicating that Fg may not be significantly associated with angiogenesis in certain contexts. Tumor analysis from Fg-deficient mice and normal controls exhibited no genotype-dependent variations in vessel density and pattern (113). In regions with heightened Fg leakage, quantifying vascular density revealed no alterations in blood vessel size or density, dissociating elevated plasma Fg from angiogenesis (114).

2.5 Fg and metastasis

The coagulation cascade and platelet activation stand as pivotal drivers of metastasis, orchestrating a multifaceted interplay in tumor progression. Fibrinogen(Fg), a crucial constituent of the tumor microenvironment, facilitates tumor metastasis via both platelet-dependent and platelet-independent pathways.

Initially, Fg may foster tumor metastasis through platelet-dependent mechanisms. Platelets, circulating in the bloodstream, emerge as essential accomplices in facilitating tumor metastasis, underscoring their intricate involvement in the metastatic cascade. Platelet membranes host a myriad of adhesion molecules, including integrin α₆β₁, α_vβ₃and α_IIbβ₃, emerges as a critical mediator in platelet-tumor cell interactions, particularly through its facilitation of integrin α_vβ₃ binding to tumor cells (115). Moreover, he interaction between platelet integrin α_IIbβ₃ and specific Fg sequences, such as γA400-411 and arginine-glycine-aspartic acid(RGD) (116), enhances cancer cell adhesion to endothelial cells, fostering the dissemination of tumor cells (116, 117). Notably, studies in mice lacking Fg and Gαq, a G protein pivotal for platelet activation, showcased significantly reduced tumor cell survival compared to control counterparts (118, 119). This underscores the potential of Fg in bolstering platelet-tumor cell interactions, thereby modulating the metastatic potential mediated by platelets.

However, divergent perspectives exist regarding the role of Fg in cancer metastasis independent of platelets. Fg β15-42 emerges as a key player in augmenting vascular permeability and facilitating tumor cell migration across endothelial cells by binding to VE-cadherin (60). Furthermore, Fg serves as a mediator for matrix metalloproteinase (MMP)-2 and MMP-9, pivotal enzymes involved in tumor metastasis, by participating in extracellular matrix remodeling (74). These findings underscore Fg’s intricate involvement in regulating tumor cell migration during metastasis by integrating into the ECM and modulating matrix composition (120) (Figure 3).

Figure 3

Furthermore, Fg can directly interact with tumor cells, thereby enhancing their metastatic potential. Fg plays a pivotal role in fostering persistent adherence, survival of metastatic emboli post-tumor cell intravasation, and contributes significantly to spontaneous metastasis (25, 27). Interactions between cancer cells and Fg, particularly in cases where cancer cells express ICAM-1, expedite endothelial penetration for metastasis by forming Fg-dependent bridges (121). Furthermore, the citrullination of Fg by lung endothelial cells promotes tumor cell aggregation and enhances metastatic potential (122).

Insights derived from studies involving Fg-deficient mice provide valuable illumination into the multifaceted role of Fg in metastasis. These investigations have yielded evidence showcasing a measurable reduction in lung micro-metastasis or overall tumor burden in the absence of Fg (113, 123). Crucially, this quantitative decline doesn’t correlate with observable changes in tumor stroma development or the general growth pattern of tumors. It’s noteworthy that the reduction in metastatic occurrences, though significant, falls short of achieving complete elimination. This intriguing observation was consistent across models involving Lewis lung carcinoma and the B16-BL6 melanoma, indicating a nuanced relationship between Fg and the metastatic process (124). This nuanced interplay suggests that while Fg deficiency exerts a discernible impact, it does not entirely eradicate metastatic events, prompting a deeper exploration into the specific mechanisms and contexts governing the complex interaction between Fg and metastasis.

Contrastingly, evidence supporting an anti-metastatic role for Fg and its fragments also exists. In a Met-1 breast cancer nude mouse model injected with the γC truncation mutant (γC399tr), reduced metastasis was observed compared to control mice, indicating the potential of γC399tr in impeding tumor growth (107). Additional findings revealed that in vivo subcutaneous injection of fibrinogen Aα(FGA) knockout (KO) A549 cells into immunodeficient BALB/c nude mice led to increased A549 cell proliferation and colonization, suggesting an inhibitory role of Fg in this context (125). Moreover, a unique perspective posits Fg’s anti-metastatic influence in anatomical sites characterized by low Fg concentrations, such as lymphatics and body cavities. Schneider et al.’s hypothesis suggesting the suppression of tumor cell migration by Fg, acting as a counterforce to free vitronectin, adds a layer of complexity to our understanding of Fg’s diverse roles in metastasis (126).

These multifaceted observations underscore the intricate and context-dependent nature of Fg’s impact on metastatic processes, warranting further exploration to decipher the nuanced interplay between Fg and tumor metastasis.

2.6 Molecular pathways of Fg in regulation of tumor progression

Currently, investigations into the relationship between Fibrinogen (Fg) and tumors predominantly center around clinical data analysis, with a limited number of studies delving into the intricate molecular mechanisms at play. In diverse tumor microenvironments, the molecular pathways involving Fg exhibit variability, indicating the multifaceted role of Fg in tumorigenesis.

In the context of lung adenocarcinoma (LUAD), Fg typically promotes tumor proliferation and metastasis, Fibrinogen Aα(FGA) exerts inhibitory effects on tumor growth, metastasis, and invasion while fostering apoptosis through the suppression of the PI3K-AKT-mTOR pathway (125).

Shifting focus to esophageal squamous cell carcinoma (ESCC), Fg demonstrates a distinctive impact. Here, Fg is implicated in the promotion of cell migration and invasion, albeit without a significant influence on proliferation. This nuanced effect is achieved through the induction of Epithelial-Mesenchymal Transition (EMT) via the p-AKT/p-mTOR pathway (8). In some ESCC patients with elevated Fg, TP53, KMT2D, and NOTCH1 actionable gene variants were detected, but the specific signaling pathways remain to be studied (20).

Moving to colon cancer, the interaction between Fg and tumor cells is facilitated by the activation of Focal Adhesion Kinase (FAK), concurrently inhibiting the tumor suppressor p53 and its downstream targets, such as 14-3-3σ and p21. This concerted action promotes unbridled cell growth while inhibiting senescence (67).

Within the intricacies of the hepatocellular carcinoma (HCC) microenvironment, Fg emerges as a pivotal player, exerting its influence through interactions with integrin αvβ5 and subsequent activation of hepatic stellate cells (HSCs). This interaction establishes a robust correlation with both the incidence and recurrence of HCC in affected individuals (5). Fg’s impact extends beyond mere association, actively promoting migration and invasion of hepatocellular carcinoma cells. These pro-metastatic effects are mediated through the activation of the PTEN/AKT/mTOR pathway, coupled with the induction of epithelial-mesenchymal transition (EMT) (127). Furthermore, in hepatoma cell lines, the expression of Fg undergoes significant modulation. This modulation is intricately linked to the degradation of signal transducer and activator of transcription (STAT), providing a glimpse into the regulatory mechanisms governing Fg expression (128). Significantly, the targeted inhibition of p38 MAPK demonstrates a marked ability to downregulate Fg expression, thereby illuminating a promising avenue for precision therapeutic interventions (128). This finding underscores the potential interplay between Fg and key signaling pathways, including JAK/STAT and p38 MAPK, hinting at intricate regulatory mechanisms within the cellular milieu. In addition, in HCC, fibrinogen Aα(FGA) can act as a tumor suppressor with opposite effects. It has been shown that FGA mutations can promote hepatocellular carcinoma development by activating TYK2-STAT3 signaling and increasing IL-6 expression (129). Additionally, FGA can impede AKT phosphorylation and its downstream effectors, such as Bcl-2, by binding to HBsAg, thereby diminishing pro-survival protein levels while augmenting pro-apoptotic protein expression (130). The intricate interplay of these molecular events highlights Fg’s multifaceted role in shaping the aggressive behavior of hepatocellular carcinoma.

Within gallbladder cancer (GBC) cells, Fg orchestrates a multifaceted interplay, aggregating macrophages to propel angiogenesis. This effect is mediated through the upregulation of Intercellular Adhesion Molecule-1 (ICAM-1) expression (131). Moreover, Fg induces a phenotypic shift in GBC cells, typified by an increase in the mesenchymal marker vimentin, coupled with a concomitant decrease in the epithelial marker E-cadherin. This dual modulation strongly implies that Fg plays a contributory role in cell migration and invasion, potentially through the induction of Epithelial-Mesenchymal Transition (EMT) signaling (132).

Within the intricate milieu of ovarian cancer, Fg emerges as a dynamic orchestrator, stimulating fibroblasts to enhance the production of Type I alpha 1 collagen (COL1A1). Simultaneously, Fg acts as a catalyst, activating the AKT signaling pathway (133). These concerted actions contribute to the facilitation of cancer metastasis, marking Fg as a key player in shaping the metastatic landscape of ovarian cancer.

In breast cancer, the extracellular matrix, including Fg, plays a pivotal role in modulating tumor cell behavior, particularly proliferation and quiescence, through mechanical stimuli. Lower mechanical forces stimulate the cytoskeleton/AIRE axis via integrin β1/3 receptor activation, enhancing tumor cell potential. Conversely, excessive mechanical forces activate DDR2/STAT1/P27 signaling, inducing cell cycle arrest and transitioning stem cell-like cancer cells into a quiescent state (134).

This nuanced understanding of Fg regulation offers valuable insights into the potential synergies between different signaling cascades (Figure 4), providing a foundation for the development of targeted therapeutic strategies aimed at modulating Fg-mediated pathways in disease states.

Figure 4

3 Discussion

The existing comprehension of the relationships between Fibrinogen (Fg) and tumors primarily rests on clinical data, consistently indicating that elevated plasma Fg levels serve as independent predictors for an unfavorable prognosis across various tumor types. A mounting body of evidence underscores Fg’s multifaceted role in promoting tumorigenesis, encompassing pro-inflammatory, metastatic, and angiogenic effects that collectively contribute to tumor progression.

Based on our thorough literature review, we anticipate significant potential for further development in understanding the relationship between Fg and tumors. Primarily, in clinical contexts, Fg determination methods need not be confined solely to plasma analysis, such as the traditional Clauss method; exploring liquid biopsy (135) or salivary Fg detection (136) could shed light on Fg’s prognostic implications for tumors. There is a pressing need for more comprehensive studies on how Fg levels may interfere with various chemotherapy regimens and impact the development of therapy resistance. Furthermore, future investigations could delve into the prognostic significance of plasma Fg ratios when combined with other tumor prognostic markers, such as the fibrinogen-to-albumin ratio (137, 138), F-NLR (fibrinogen and neutrophil-lymphocyte ratio) (139), among others. Additionally, there is scope for further exploration of the roles played by Fg fragments, including FGA, FGB, and FGG, in the context of tumor prognosis.

In terms of basic research, while the prognostic significance of plasma Fg in various tumors has been extensively investigated, several areas warrant further exploration. These include elucidating the mechanisms underlying the association between elevated Fg levels prior to treatment and the subsequent poor prognosis of cancer patients post-surgery or chemotherapy. Additionally, the mechanisms governing Fg deposition within the microenvironment of diverse tumor types, as well as its involvement in processes such as inflammation, angiogenesis, and metastasis, require thorough investigation. Future studies could focus on uncovering the intricate molecular mechanisms through which Fg influences tumor progression across different cancer types. This could involve identifying specific integrins that interact with Fg, elucidating downstream effector molecules modulated by Fg, and assessing the potential relevance of these Fg-mediated signaling pathways in various human tumors. Furthermore, in terms of experimental protocol development, research targeting Fg as a therapeutic target has primarily been limited to a few tumor cell lines or murine models, neglecting the broader spectrum of tumor types. Given the challenges associated with Fg deficiency and its implications for hemostasis, refining experimental protocols is imperative. More precise methodologies are urgently needed to facilitate in situ injection of cancer cell lines into Fg-knockout mice, enabling a more comprehensive understanding of Fg’s role in tumor biology. Lastly, there is scope to expand investigations into the interactions between Fg-related fragments and tumors, which may yield novel insights. Exploring these interactions could uncover unexpected findings and contribute to a deeper understanding of the complex interplay between Fg and tumorigenesis.

The translation of relevant research findings on Fg and tumors into clinical applications is a promising endeavor that can significantly impact tumor treatment protocols. Firstly, our review findings suggest a strong association between elevated pretreatment Fg levels and poor prognosis in most tumor patients. This association can serve as a valuable guide for determining treatment regimens and post-treatment management strategies for cancer patients. Additionally, compared to current tumor markers that often involve cumbersome testing steps like immunohistochemistry, assessing Fg levels through pre-treatment coagulation is more convenient, accessible, and provides a quicker reference value. Secondly, Fg can serve as a tool for stratifying and assessing individual tumor risk. Particularly in cases where tumors lack precise and specific prognostic biomarkers, plasma Fg offers significant clinical utility. Furthermore, specific fragments of Fg, such as FGA, FGB, and FGG, may exert distinct effects on tumors compared to intact Fg. For instance, FGA may function as an inhibitory factor, presenting itself as a potential target for clinical interventions and tumor treatments. Lastly, targeting Fg to mitigate its role in promoting tumorigenesis and development holds promise for innovative cancer treatments. Strategies like partial inhibition of the Fg gene or blocking downstream signaling pathways activated by Fg could prevent its involvement in tumor metastasis and angiogenesis. These approaches offer new avenues for cancer treatment and have the potential to enhance the effectiveness and customization of therapeutic strategies.

References

• 1

  Kant JA Fornace AJ Jr. Saxe D Simon MI McBride OW Crabtree GR . Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U.S.A. (1985) 82:2344–8. doi: 10.1073/pnas.82.8.2344

  • CrossRef
  • Google Scholar

• 2

  Mosesson MW . Fibrinogen and fibrin structure and functions. J Thromb Haemost. (2005) 3:1894–904. doi: 10.1111/j.1538-7836.2005.01365.x

  • CrossRef
  • Google Scholar

• 3

  Luyendyk JP Schoenecker JG Flick MJ . The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. (2019) 133:511–20. doi: 10.1182/blood-2018-07-818211

  • CrossRef
  • Google Scholar

• 4

  Perisanidis C Psyrri A Cohen EE Engelmann J Heinze G Perisanidis B et al . Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis. Cancer Treat Rev. (2015) 41:960–70. doi: 10.1016/j.ctrv.2015.10.002

  • CrossRef
  • Google Scholar

• 5

  Yan C Yang Q Gong Z . Activation of hepatic stellate cells during liver carcinogenesis requires fibrinogen/integrin Avβ5 in Zebrafish. Neoplasia. (2018) 20:533–42. doi: 10.1016/j.neo.2018.02.002

  • CrossRef
  • Google Scholar

• 6

  Halder SK Milner R . The impact of chronic mild hypoxia on cerebrovascular remodelling; uncoupling of angiogenesis and vascular breakdown. Fluids Barriers CNS. (2021) 18:50. doi: 10.1186/s12987-021-00284-x

  • CrossRef
  • Google Scholar

• 7

  Wolberg AS . Fibrinogen and fibrin: synthesis, structure, and function in health and disease. J Thromb Haemost. (2023) 21:3005–15. doi: 10.1016/j.jtha.2023.08.014

  • CrossRef
  • Google Scholar

• 8

  Zhang F Wang Y Sun P Wang ZQ Wang DS Zhang DS et al . Fibrinogen promotes Malignant biological tumor behavior involving epithelial-mesenchymal transition via the P-akt/P-mtor pathway in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. (2017) 143:2413–24. doi: 10.1007/s00432-017-2493-4

  • CrossRef
  • Google Scholar

• 9

  Beleva EA Deneva TI Stoencheva SS Grudeva-Popova ZG . Longitudinal dynamics of coagulation and angiogenesis markers in cancer patients during and after chemotherapy. Clin Appl Thromb Hemost. (2021) 27:10760296211056637. doi: 10.1177/10760296211056637

  • CrossRef
  • Google Scholar

• 10

  Cheng F Zeng C Zeng L Chen Y . Clinicopathological and prognostic value of preoperative plasma fibrinogen in gastric cancer patients: A meta-analysis. Med (Baltimore). (2019) 98:e17310. doi: 10.1097/md.0000000000017310

  • CrossRef
  • Google Scholar

• 11

  Lee JH Hyun JH Kim DY Yoo BC Park JW Kim SY et al . The role of fibrinogen as a predictor in preoperative chemoradiation for rectal cancer. Ann Surg Oncol. (2015) 22:209–15. doi: 10.1245/s10434-014-3962-5

  • CrossRef
  • Google Scholar

• 12

  Cai H Zhang ZH Zhou YJ Liu J Chen HQ Lin RY . The prognostic value of preoperative plasma fibrinogen and neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma. Ear Nose Throat J. (2021) 100:731–6. doi: 10.1177/0145561320920746

  • CrossRef
  • Google Scholar

• 13

  He SS Wang Y Yang L Chen HY Liang SB Lu LX et al . Plasma fibrinogen correlates with metastasis and is associated with prognosis in human nasopharyngeal carcinoma. J Cancer. (2017) 8:403–9. doi: 10.7150/jca.17028

  • CrossRef
  • Google Scholar

• 14

  Fan S Guan Y Zhao G An G . Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma. Thorac Cancer. (2018) 9:146–51. doi: 10.1111/1759-7714.12556

  • CrossRef
  • Google Scholar

• 15

  Mitsui S Tanaka Y Doi T Hokka D Maniwa Y . Prognostic value of preoperative plasma fibrinogen levels in resected stage I non-small cell lung cancer. Thorac Cancer. (2022) 13:1490–5. doi: 10.1111/1759-7714.14419

  • CrossRef
  • Google Scholar

• 16

  Sinn K Mosleh B Grusch M Klepetko W Hoetzenecker K Klikovits T et al . Impact of fibrinogen levels and modified glasgow prognostic score on survival of stage iii/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection. BMC Cancer. (2022) 22:1197. doi: 10.1186/s12885-022-10298-9

  • CrossRef
  • Google Scholar

• 17

  Su Z Huang J Chen W Sun A Bai X Huang L et al . High diagnostic value of plasma fibrinogen for osteomyelitis of the jaws after oral cancer surgery. Oral Dis. (2022) 28:1907–10. doi: 10.1111/odi.13911

  • CrossRef
  • Google Scholar

• 18

  Wu M Ye P Zhang W Zhu H Yu H . Prognostic role of an inflammation scoring system in radical resection of oral squamous cell carcinoma. BMC Oral Health. (2022) 22:226. doi: 10.1186/s12903-022-02261-8

  • CrossRef
  • Google Scholar

• 19

  Wakatsuki K Matsumoto S Migita K Ito M Kunishige T Nakade H et al . Preoperative plasma fibrinogen is associated with lymph node metastasis and predicts prognosis in resectable esophageal cancer. World J Surg. (2017) 41:2068–77. doi: 10.1007/s00268-017-3991-x

  • CrossRef
  • Google Scholar

• 20

  Hoshino S Matsuda S Kawakubo H Yamaguchi S Nakamura K Aimono E et al . Elevation of the prognostic factor plasma fibrinogen reflects the immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma. Ann Surg Oncol. (2022) 29:6894–904. doi: 10.1245/s10434-022-11974-7

  • CrossRef
  • Google Scholar

• 21

  Wang H Yin X Ma K Wang Y Fang T Zhang Y et al . Nomogram based on preoperative fibrinogen and systemic immune-inflammation index predicting recurrence and prognosis of patients with borrmann type iii advanced gastric cancer. J Inflammation Res. (2023) 16:1059–75. doi: 10.2147/jir.S404585

  • CrossRef
  • Google Scholar

• 22

  Parisi R Panzera T Russo L Gamba S De Curtis A Di Castelnuovo A et al . Fibrinogen levels in relation to colorectal cancer onset: A nested case-cohort study from the moli-sani cohort. Front Cardiovasc Med. (2022) 9:1009926. doi: 10.3389/fcvm.2022.1009926

  • CrossRef
  • Google Scholar

• 23

  Huang G Jiang H Lin Y Wu Y Cai W Shi B et al . Prognostic value of plasma fibrinogen in hepatocellular carcinoma: A meta-analysis. Cancer Manag Res. (2018) 10:5027–41. doi: 10.2147/cmar.S175780

  • CrossRef
  • Google Scholar

• 24

  Xu J An S Lu Y Li L Wu ZQ Xu HG . Preoperative alpha fetoprotein, total bilirubin, fibrinogen, albumin, and lymphocytes predict postoperative survival in hepatocellular carcinoma. Cancer Med. (2023) 12:13319–28. doi: 10.1002/cam4.6030

  • CrossRef
  • Google Scholar

• 25

  Guo Q Zhang B Dong X Xie Q Guo E Huang H et al . Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas. (2009) 38:e75–9. doi: 10.1097/MPA.0b013e3181987d86

  • CrossRef
  • Google Scholar

• 26

  Chung KH Lee JC Lee J Cho IK Kim J Jang W et al . Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Pancreatology. (2020) 20:1465–71. doi: 10.1016/j.pan.2020.06.010

  • CrossRef
  • Google Scholar

• 27

  Ye XW Hu HJ Xiong XZ Lu J Cheng NS . The preoperative elevated plasma fibrinogen level is associated with the prognosis of hilar cholangiocarcinoma. Surg Today. (2021) 51:1352–60. doi: 10.1007/s00595-021-02249-x

  • CrossRef
  • Google Scholar

• 28

  Cao P Jiang L Zhou LY Chen YL . The clinical significance of preoperative serum fibrinogen levels and platelet counts in patients with gallbladder carcinoma. BMC Gastroenterol. (2021) 21:366. doi: 10.1186/s12876-021-01943-x

  • CrossRef
  • Google Scholar

• 29

  Lu J Chen S Li X Qiu G He S Wang H et al . Gastrointestinal stromal tumors: fibrinogen levels are associated with prognosis of patients as blood-based biomarker. Med (Baltimore). (2018) 97:e0568. doi: 10.1097/md.0000000000010568

  • CrossRef
  • Google Scholar

• 30

  Troppan KT Melchardt T Wenzl K Schlick K Deutsch A Bullock MD et al . The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. J Clin Pathol. (2016) 69:326–30. doi: 10.1136/jclinpath-2015-203356

  • CrossRef
  • Google Scholar

• 31

  Zhang Z Zhang R Qi J Miao W Fang K Ruan C et al . The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: A systematic review and meta-analysis. Leuk Lymphoma. (2020) 61:2682–91. doi: 10.1080/10428194.2020.1780587

  • CrossRef
  • Google Scholar

• 32

  Holtzman NG Xie H Bentzen S Kesari V Bukhari A El Chaer F et al . Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol. (2021) 23:112–21. doi: 10.1093/neuonc/noaa183

  • CrossRef
  • Google Scholar

• 33

  Tian Y Hong M Jing S Liu X Wang H Wang X et al . Clinical and prognostic effect of plasma fibrinogen in renal cell carcinoma: A meta-analysis. BioMed Res Int. (2017) 2017:9591506. doi: 10.1155/2017/9591506

  • CrossRef
  • Google Scholar

• 34

  Liu R Zhou X Zou L Chen Q Hu Y Hu J et al . Clinicopathological and prognostic significance of preoperative plasma fibrinogen level in patients with upper urinary tract urothelial carcinoma: A retrospective tumor marker prognostic study. Int J Surg. (2019) 65:88–93. doi: 10.1016/j.ijsu.2019.03.022

  • CrossRef
  • Google Scholar

• 35

  Polterauer S Seebacher V Hefler-Frischmuth K Grimm C Heinze G Tempfer C et al . Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol. (2009) 200:647. doi: 10.1016/j.ajog.2009.01.008

  • CrossRef
  • Google Scholar

• 36

  Seebacher V Aust S D’Andrea D Grimm C Reiser E Tiringer D et al . Development of a tool for prediction of ovarian cancer in patients with adnexal masses: value of plasma fibrinogen. PloS One. (2017) 12:e0182383. doi: 10.1371/journal.pone.0182383

  • CrossRef
  • Google Scholar

• 37

  Farzaneh F Salimnezhad M Hosseini MS Ashraf Ganjouee T Arab M Talayeh M . D-dimer, fibrinogen and tumor marker levels in patients with benign and Malignant ovarian tumors. Asian Pac J Cancer Prev. (2023) 24:4263–8. doi: 10.31557/apjcp.2023.24.12.4263

  • CrossRef
  • Google Scholar

• 38

  Hefler-Frischmuth K Lafleur J Hefler L Polterauer S Seebacher V Reinthaller A et al . Plasma fibrinogen levels in patients with benign and Malignant ovarian tumors. Gynecol Oncol. (2015) 136:567–70. doi: 10.1016/j.ygyno.2014.12.041

  • CrossRef
  • Google Scholar

• 39

  Bekos C Grimm C Brodowicz T Petru E Hefler L Reimer D et al . Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study. Sci Rep. (2017) 7:14474. doi: 10.1038/s41598-017-13934-8

  • CrossRef
  • Google Scholar

• 40

  Seebacher V Polterauer S Grimm C Husslein H Leipold H Hefler-Frischmuth K et al . The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: A multi-centre trial. Br J Cancer. (2010) 102:952–6. doi: 10.1038/sj.bjc.6605547

  • CrossRef
  • Google Scholar

• 41

  Wang Y Yin W Wang Z Huang J Pan J Zhu Y et al . Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy. Prostate Cancer Prostatic Dis. (2016) 19:209–15. doi: 10.1038/pcan.2016.6

  • CrossRef
  • Google Scholar

• 42

  Li X Shu K Zhou J Yu Q Cui S Liu J et al . Preoperative plasma fibrinogen and D-dimer as prognostic biomarkers for non-muscle-invasive bladder cancer. Clin Genitourin Cancer. (2020) 18:11–9.e1. doi: 10.1016/j.clgc.2019.10.025

  • CrossRef
  • Google Scholar

• 43

  Graf ME Sookthai D Johnson T Schübel R Maldonado SG Pletsch-Borba L et al . Pre-diagnostic plasma concentrations of fibrinogen, sgpiib/iiia, sp-selectin, sthrombomodulin, thrombopoietin in relation to cancer risk: findings from a large prospective study. Int J Cancer. (2018) 143:2659–67. doi: 10.1002/ijc.31623

  • CrossRef
  • Google Scholar

• 44

  Wang Y Wang Y Chen R Tang Z Peng Y Jin Y et al . Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: A retrospective study of 1004 Chinese breast cancer patients. BMC Cancer. (2021) 21:542. doi: 10.1186/s12885-021-08284-8

  • CrossRef
  • Google Scholar

• 45

  Jianyong L Zhihui L Rixiang G Jingqiang Z . Using a nomogram based on preoperative serum fibrinogen levels to predict recurrence of papillary thyroid carcinoma. BMC Cancer. (2018) 18:390. doi: 10.1186/s12885-018-4296-7

  • CrossRef
  • Google Scholar

• 46

  Wang PF Meng Z Song HW Yao K Duan ZJ Li SW et al . Higher plasma fibrinogen levels are associated with Malignant phenotype and worse survival in patients with glioblastomas. J Cancer. (2018) 9:2024–9. doi: 10.7150/jca.24714

  • CrossRef
  • Google Scholar

• 47

  Ghanim B Hoda MA Klikovits T Winter MP Alimohammadi A Grusch M et al . Circulating fibrinogen is a prognostic and predictive biomarker in Malignant pleural mesothelioma. Br J Cancer. (2014) 110:984–90. doi: 10.1038/bjc.2013.815

  • CrossRef
  • Google Scholar

• 48

  Asanuma K Matsumine A Nakamura T Matsubara T Asanuma Y Oi T et al . Impact of plasma fibrinogen levels in benign and Malignant soft tissue tumors. Cancer biomark. (2016) 16:453–8. doi: 10.3233/cbm-160584

  • CrossRef
  • Google Scholar

• 49

  Pu Y Wang J Wang J Wang S . Association of preoperative plasma D-dimer and fibrinogen and osteosarcoma outcome. Front Oncol. (2022) 12:699295. doi: 10.3389/fonc.2022.699295

  • CrossRef
  • Google Scholar

• 50

  Peschek LS Hobusch GM Funovics PT Willegger M Schmid MP Amann G et al . High fibrinogen levels are associated with poor survival in patients with liposarcoma. Sci Rep. (2023) 13:8608. doi: 10.1038/s41598-023-31527-6

  • CrossRef
  • Google Scholar

• 51

  Nenclares P Gunn L Soliman H Bover M Trinh A Leslie I et al . On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. J Immunother Cancer. (2021) 9(6). doi: 10.1136/jitc-2021-002718

  • CrossRef
  • Google Scholar

• 52

  Liang YJ Mei XY Zeng B Zhang SE Yang L Lao XM et al . Prognostic role of preoperative D-dimer, fibrinogen and platelet levels in patients with oral squamous cell carcinoma. BMC Cancer. (2021) 21:122. doi: 10.1186/s12885-021-07841-5

  • CrossRef
  • Google Scholar

• 53

  Mori S Taki T Murakami Y Urata T Okumura M Akanabe H et al . Low plasma fibrinogen levels are associated with poor prognosis in cutaneous angiosarcoma of the head and neck. Cancer Sci. (2021) 112:3924–7. doi: 10.1111/cas.15037

  • CrossRef
  • Google Scholar

• 54

  Chu T Wang H Lv X Qi J Tang Y Fan Y et al . Investigation of fibrinogen in early bleeding of patients with newly diagnosed acute promyelocytic leukemia. Platelets. (2021) 32:677–83. doi: 10.1080/09537104.2020.1799969

  • CrossRef
  • Google Scholar

• 55

  Zhang X Long Q . Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients. Med (Baltimore). (2017) 96:e6694. doi: 10.1097/md.0000000000006694

  • CrossRef
  • Google Scholar

• 56

  Dvorak HF . Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. (1986) 315:1650–9. doi: 10.1056/nejm198612253152606

  • CrossRef
  • Google Scholar

• 57

  Rybarczyk BJ Simpson-Haidaris PJ . Fibrinogen assembly, secretion, and deposition into extracellular matrix by mcf-7 human breast carcinoma cells. Cancer Res. (2000) 60:2033–9.

  • Google Scholar

• 58

  Lee SY Lee KP Lim JW . Identification and biosynthesis of fibrinogen in human uterine cervix carcinoma cells. Thromb Haemost. (1996) 75:466–70.

  • Google Scholar

• 59

  Chan JP Merlini M Gao HX Mendiola AS Akassoglou K Rubenstein JL et al . Blood coagulation factor fibrinogen in tumor pathogenesis of central nervous system B-cell lymphoma. Am J Pathol. (2021) 191:575–83. doi: 10.1016/j.ajpath.2020.12.010

  • CrossRef
  • Google Scholar

• 60

  Sahni A Arévalo MT Sahni SK Simpson-Haidaris PJ . The ve-cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of Malignant breast epithelial cells. Int J Cancer. (2009) 125:577–84. doi: 10.1002/ijc.24340

  • CrossRef
  • Google Scholar

• 61

  Lip GY Chin BS Blann AD . Cancer and the prothrombotic state. Lancet Oncol. (2002) 3:27–34. doi: 10.1016/s1470-2045(01)00619-2

  • CrossRef
  • Google Scholar

• 62

  Wang C Wang Y Zuo N Fang S Shi J . Cd44-fibrinogen binding promotes bleeding in acute promyelocytic leukemia by in situ fibrin(Ogen) deposition. Blood Adv. (2022) 6:4617–33. doi: 10.1182/bloodadvances.2022006980

  • CrossRef
  • Google Scholar

• 63

  Guadiz G Sporn LA Simpson-Haidaris PJ . Thrombin cleavage-independent deposition of fibrinogen in extracellular matrices. Blood. (1997) 90:2644–53. doi: 10.1182/blood.V90.7.2644

  • CrossRef
  • Google Scholar

• 64

  Redman CM Xia H . Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion. Ann N Y Acad Sci. (2001) 936:480–95. doi: 10.1111/j.1749-6632.2001.tb03535.x

  • CrossRef
  • Google Scholar

• 65

  Zhang W Gao Z Zeng G Xie H Liu J Liu N et al . Clinical significance of urinary plasminogen and fibrinogen gamma chain as novel potential diagnostic markers for non-small-cell lung cancer. Clin Chim Acta. (2020) 502:55–65. doi: 10.1016/j.cca.2019.11.022

  • CrossRef
  • Google Scholar

• 66

  Liu G Xu X Geng H Li J Zou S Li X . Fga inhibits metastases and induces autophagic cell death in gastric cancer via inhibiting itga5 to regulate the fak/erk pathway. Tissue Cell. (2022) 76:101767. doi: 10.1016/j.tice.2022.101767

  • CrossRef
  • Google Scholar

• 67

  Sharma BK Mureb D Murab S Rosenfeldt L Francisco B Cantrell R et al . Fibrinogen activates focal adhesion kinase (Fak) promoting colorectal adenocarcinoma growth. J Thromb Haemost. (2021) 19:2480–94. doi: 10.1111/jth.15440

  • CrossRef
  • Google Scholar

• 68

  Adams GN Rosenfeldt L Frederick M Miller W Waltz D Kombrinck K et al . Colon cancer growth and dissemination relies upon thrombin, stromal par-1, and fibrinogen. Cancer Res. (2015) 75:4235–43. doi: 10.1158/0008-5472.Can-15-0964

  • CrossRef
  • Google Scholar

• 69

  Zhang X Wang F Huang Y Ke K Zhao B Chen L et al . Fgg promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition. Cancer Manag Res. (2019) 11:1653–65. doi: 10.2147/cmar.S188248

  • CrossRef
  • Google Scholar

• 70

  Masamune A Kikuta K Watanabe T Satoh K Hirota M Hamada S et al . Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut. (2009) 58:550–9. doi: 10.1136/gut.2008.154401

  • CrossRef
  • Google Scholar

• 71

  Verheul HM van Erp K Homs MY Yoon GS van der Groep P Rogers C et al . The relationship of vascular endothelial growth factor and coagulation factor (Fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology. (2010) 75:608–14. doi: 10.1016/j.urology.2009.05.075

  • CrossRef
  • Google Scholar

• 72

  Chen Y Zhu Y Sheng Y Xiao J Xiao Y Cheng N et al . Sirt1 downregulated fgb expression to inhibit rcc tumorigenesis by destabilizing stat3. Exp Cell Res. (2019) 382:111466. doi: 10.1016/j.yexcr.2019.06.011

  • CrossRef
  • Google Scholar

• 73

  Uccella S Cromi A Vigetti D Cimetti L Deleonibus S Casarin J et al . Endometrial cancer cells can express fibrinogen: immunohistochemistry and Rt-Pcr analysis. J Obstet Gynaecol. (2016) 36:353–8. doi: 10.3109/01443615.2015.1065231

  • CrossRef
  • Google Scholar

• 74

  Dzikowski L Mirzaei R Sarkar S Kumar M Bose P Bellail A et al . Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor-initiating cells. Brain Pathol. (2021) 31:e12947. doi: 10.1111/bpa.12947

  • CrossRef
  • Google Scholar

• 75

  Teitelbaum DH Tuttle S Carey LC Clausen KP . Fibrolamellar carcinoma of the liver. Review of three cases and the presentation of a characteristic set of tumor markers defining this tumor. Ann Surg. (1985) 202:36–41. doi: 10.1097/00000658-198507000-00005

  • CrossRef
  • Google Scholar

• 76

  Greten FR Grivennikov SI . Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. (2019) 51:27–41. doi: 10.1016/j.immuni.2019.06.025

  • CrossRef
  • Google Scholar

• 77

  Cervantes-Villagrana RD Albores-García D Cervantes-Villagrana AR García-Acevez SJ . Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. (2020) 5:99. doi: 10.1038/s41392-020-0205-z

  • CrossRef
  • Google Scholar

• 78

  Zhang C Chen H He Q Luo Y He A Tao A et al . Fibrinogen/akt/microfilament axis promotes colitis by enhancing vascular permeability. Cell Mol Gastroenterol Hepatol. (2021) 11:683–96. doi: 10.1016/j.jcmgh.2020.10.007

  • CrossRef
  • Google Scholar

• 79

  Hahn J Bressler J Domingo-Relloso A Chen MH McCartney DL Teumer A et al . DNA methylation analysis is used to identify novel genetic loci associated with circulating fibrinogen levels in blood. J Thromb Haemost. (2023) 21:1135–47. doi: 10.1016/j.jtha.2023.01.015

  • CrossRef
  • Google Scholar

• 80

  Tsakadze NL Zhao Z D’Souza SE . Interactions of intercellular adhesion molecule-1 with fibrinogen. Trends Cardiovasc Med. (2002) 12:101–8. doi: 10.1016/s1050-1738(01)00157-8

  • CrossRef
  • Google Scholar

• 81

  Davalos D Ryu JK Merlini M Baeten KM Le Moan N Petersen MA et al . Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun. (2012) 3:1227. doi: 10.1038/ncomms2230

  • CrossRef
  • Google Scholar

• 82

  Han CY Pichon TJ Wang X Ringgold KM St John AE Stern SA et al . Leukocyte activation primes fibrinogen for proteolysis by mitochondrial oxidative stress. Redox Biol. (2022) 51:102263. doi: 10.1016/j.redox.2022.102263

  • CrossRef
  • Google Scholar

• 83

  Millien VO Lu W Shaw J Yuan X Mak G Roberts L et al . Cleavage of fibrinogen by proteinases elicits allergic responses through toll-like receptor 4. Science. (2013) 341:792–6. doi: 10.1126/science.1240342

  • CrossRef
  • Google Scholar

• 84

  Jensen T Kierulf P Sandset PM Klingenberg O Joø GB Godal HC et al . Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from isolated peripheral blood mononuclear cells. Thromb Haemost. (2007) 97:822–9. doi: 10.1160/th07-01-0039

  • CrossRef
  • Google Scholar

• 85

  Saraiva AL Peres RS Veras FP Talbot J de Lima KA Luiz JPM et al . Citrullinated human fibrinogen triggers arthritis through an inflammatory response mediated by il-23/il-17 immune axis. Int Immunopharmacol. (2021) 101:108363. doi: 10.1016/j.intimp.2021.108363

  • CrossRef
  • Google Scholar

• 86

  Smiley ST King JA Hancock WW . Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol. (2001) 167:2887–94. doi: 10.4049/jimmunol.167.5.2887

  • CrossRef
  • Google Scholar

• 87

  Guo M Sahni SK Sahni A Francis CW . Fibrinogen regulates the expression of inflammatory chemokines through nf-kappab activation of endothelial cells. Thromb Haemost. (2004) 92:858–66. doi: 10.1160/th04-04-0261

  • CrossRef
  • Google Scholar

• 88

  Sulimai N Brown J Lominadze D . The role of nuclear factor-kappa B in fibrinogen-induced inflammatory responses in cultured primary neurons. Biomolecules. (2022) 12(12). doi: 10.3390/biom12121741

  • CrossRef
  • Google Scholar

• 89

  Alouffi S Khanam A Husain A Akasha R Rabbani G Ahmad S . D-ribose-mediated glycation of fibrinogen: role in the induction of adaptive immune response. Chem Biol Interact. (2022) 367:110147. doi: 10.1016/j.cbi.2022.110147

  • CrossRef
  • Google Scholar

• 90

  Poole LG Kopec AK Flick MJ Luyendyk JP . Cross-linking by tissue transglutaminase-2 alters fibrinogen-directed macrophage proinflammatory activity. J Thromb Haemost. (2022) 20:1182–92. doi: 10.1111/jth.15670

  • CrossRef
  • Google Scholar

• 91

  Kim JW Jeong MH Yu HT Park YJ Kim HS Chung KH . Fibrinogen on extracellular vesicles derived from polyhexamethylene guanidine phosphate-exposed mice induces inflammatory effects via integrin B. Ecotoxicol Environ Saf. (2023) 252:114600. doi: 10.1016/j.ecoenv.2023.114600

  • CrossRef
  • Google Scholar

• 92

  Flick MJ Du X Witte DP Jirousková M Soloviev DA Busuttil SJ et al . Leukocyte engagement of fibrin(Ogen) via the integrin receptor Alphambeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. (2004) 113:1596–606. doi: 10.1172/jci20741

  • CrossRef
  • Google Scholar

• 93

  Wright SD Weitz JI Huang AJ Levin SM Silverstein SC Loike JD . Complement receptor type three (Cd11b/Cd18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci U.S.A. (1988) 85:7734–8. doi: 10.1073/pnas.85.20.7734

  • CrossRef
  • Google Scholar

• 94

  Rubel C Fernández GC Rosa FA Gómez S Bompadre MB Coso OA et al . Soluble fibrinogen modulates neutrophil functionality through the activation of an extracellular signal-regulated kinase-dependent pathway. J Immunol. (2002) 168:3527–35. doi: 10.4049/jimmunol.168.7.3527

  • CrossRef
  • Google Scholar

• 95

  Ryu JK Petersen MA Murray SG Baeten KM Meyer-Franke A Chan JP et al . Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. (2015) 6:8164. doi: 10.1038/ncomms9164

  • CrossRef
  • Google Scholar

• 96

  Steinbrecher KA Horowitz NA Blevins EA Barney KA Shaw MA Harmel-Laws E et al . Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin Alpha(M)Beta(2) engagement of fibrinogen. Cancer Res. (2010) 70:2634–43. doi: 10.1158/0008-5472.Can-09-3465

  • CrossRef
  • Google Scholar

• 97

  Wichaiyo S Svasti S Supharattanasitthi W Morales NP . Dasatinib induces loss of vascular integrity and promotes cutaneous wound repair in mice. J Thromb Haemost. (2021) 19:3154–67. doi: 10.1111/jth.15499

  • CrossRef
  • Google Scholar

• 98

  Yang W Feng J Xiang F Xie Z Zhang G Sabatier JM et al . Endogenous animal toxin-like human B-defensin 2 inhibits own K(+) channels through interaction with channel extracellular pore region. Cell Mol Life Sci. (2015) 72:845–53. doi: 10.1007/s00018-014-1715-z

  • CrossRef
  • Google Scholar

• 99

  Sahni A Khorana AA Baggs RB Peng H Francis CW . Fgf-2 binding to fibrin(Ogen) is required for augmented angiogenesis. Blood. (2006) 107:126–31. doi: 10.1182/blood-2005-06-2460

  • CrossRef
  • Google Scholar

• 100

  Sahni A Simpson-Haidaris PJ Sahni SK Vaday GG Francis CW . Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (Fgf-2). J Thromb Haemost. (2008) 6:176–83. doi: 10.1111/j.1538-7836.2007.02808.x

  • CrossRef
  • Google Scholar

• 101

  Sahni A Francis CW . Stimulation of endothelial cell proliferation by Fgf-2 in the presence of fibrinogen requires alphavbeta3. Blood. (2004) 104:3635–41. doi: 10.1182/blood-2004-04-1358

  • CrossRef
  • Google Scholar

• 102

  Maciel J Oliveira MI Colton E McNally AK Oliveira C Anderson JM et al . Adsorbed fibrinogen enhances production of bone- and angiogenic-related factors by monocytes/macrophages. Tissue Eng Part A. (2014) 20:250–63. doi: 10.1089/ten.TEA.2012.0439

  • CrossRef
  • Google Scholar

• 103

  Tang H Fu Y Lei Q Han Q Ploplis VA Castellino FJ et al . Fibrinogen facilitates the anti-tumor effect of nonnative endostatin. Biochem Biophys Res Commun. (2009) 380:249–53. doi: 10.1016/j.bbrc.2009.01.045

  • CrossRef
  • Google Scholar

• 104

  Li H Cai E Cheng H Ye X Ma R Zhu H et al . Fga controls vegfa secretion to promote angiogenesis by activating the vegfr2-fak signalling pathway. Front Endocrinol (Lausanne). (2022) 13:791860. doi: 10.3389/fendo.2022.791860

  • CrossRef
  • Google Scholar

• 105

  Thiagarajan P Rippon AJ Farrell DH . Alternative adhesion sites in human fibrinogen for vascular endothelial cells. Biochemistry. (1996) 35:4169–75. doi: 10.1021/bi952532b

  • CrossRef
  • Google Scholar

• 106

  Krajewska E Lewis CE Chen YY Welford A Tazzyman S Staton CA . A novel fragment derived from the beta chain of human fibrinogen, beta43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo. Br J Cancer. (2010) 102:594–601. doi: 10.1038/sj.bjc.6605495

  • CrossRef
  • Google Scholar

• 107

  Akakura N Hoogland C Takada YK Saegusa J Ye X Liu FT et al . The cooh-terminal globular domain of fibrinogen gamma chain suppresses angiogenesis and tumor growth. Cancer Res. (2006) 66:9691–7. doi: 10.1158/0008-5472.Can-06-1686

  • CrossRef
  • Google Scholar

• 108

  Staton CA Lewis CE . Angiogenesis inhibitors found within the haemostasis pathway. J Cell Mol Med. (2005) 9:286–302. doi: 10.1111/j.1582-4934.2005.tb00356.x

  • CrossRef
  • Google Scholar

• 109

  Guo SW Che HM Li WZ . Anti-tumor effect of lentivirus-mediated gene transfer of alphastatin on human glioma. Cancer Sci. (2011) 102:1038–44. doi: 10.1111/j.1349-7006.2011.01879.x

  • CrossRef
  • Google Scholar

• 110

  Staton CA Brown NJ Rodgers GR Corke KP Tazzyman S Underwood JC et al . Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood. (2004) 103:601–6. doi: 10.1182/blood-2003-07-2192

  • CrossRef
  • Google Scholar

• 111

  Liang C Wei T Zhang T Niu C . Adipose−Derived stem cell−Mediated alphastatin targeting delivery system inhibits angiogenesis and tumor growth in glioma. Mol Med Rep. (2023) 28(5). doi: 10.3892/mmr.2023.13102

  • CrossRef
  • Google Scholar

• 112

  Chahed K Kabbage M Ehret-Sabatier L Lemaitre-Guillier C Remadi S Hoebeke J et al . Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and maldi-tof-mass spectrometry analyses. Int J Oncol. (2005) 27:1425–31. doi: 10.3892/ijo

  • CrossRef
  • Google Scholar

• 113

  Palumbo JS Potter JM Kaplan LS Talmage K Jackson DG Degen JL . Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. (2002) 62:6966–72.

  • Google Scholar

• 114

  Heinolainen K Karaman S D’Amico G Tammela T Sormunen R Eklund L et al . Vegfr3 modulates vascular permeability by controlling vegf/vegfr2 signaling. Circ Res. (2017) 120:1414–25. doi: 10.1161/circresaha.116.310477

  • CrossRef
  • Google Scholar

• 115

  Lavergne M Janus-Bell E Schaff M Gachet C Mangin PH . Platelet integrins in tumor metastasis: do they represent a therapeutic target? Cancers (Basel). (2017) 9(10). doi: 10.3390/cancers9100133

  • CrossRef
  • Google Scholar

• 116

  Huang J Li X Shi X Zhu M Wang J Huang S et al . Platelet integrin Aiibβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. (2019) 12:26. doi: 10.1186/s13045-019-0709-6

  • CrossRef
  • Google Scholar

• 117

  Schlesinger M . Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. (2018) 11:125. doi: 10.1186/s13045-018-0669-2

  • CrossRef
  • Google Scholar

• 118

  Palumbo JS Talmage KE Massari JV La Jeunesse CM Flick MJ Kombrinck KW et al . Platelets and fibrin(Ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. (2005) 105:178–85. doi: 10.1182/blood-2004-06-2272

  • CrossRef
  • Google Scholar

• 119

  Zheng S Shen J Jiao Y Liu Y Zhang C Wei M et al . Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci. (2009) 100:859–65. doi: 10.1111/j.1349-7006.2009.01115.x

  • CrossRef
  • Google Scholar

• 120

  Simpson-Haidaris PJ Rybarczyk B . Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci. (2001) 936:406–25. doi: 10.1111/j.1749-6632.2001.tb03525.x

  • CrossRef
  • Google Scholar

• 121

  Angelidakis E Chen S Zhang S Wan Z Kamm RD Shelton SE . Impact of fibrinogen, fibrin thrombi, and thrombin on cancer cell extravasation using in vitro microvascular networks. Adv Healthc Mater. (2023) 12:e2202984. doi: 10.1002/adhm.202202984

  • CrossRef
  • Google Scholar

• 122

  Han Y Tomita T Kato M Ashihara N Higuchi Y Matoba H et al . Citrullinated fibrinogen-saas complex causes vascular metastagenesis. Nat Commun. (2023) 14:4960. doi: 10.1038/s41467-023-40371-1

  • CrossRef
  • Google Scholar

• 123

  Camerer E Qazi AA Duong DN Cornelissen I Advincula R Coughlin SR . Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. (2004) 104:397–401. doi: 10.1182/blood-2004-02-0434

  • CrossRef
  • Google Scholar

• 124

  Palumbo JS Kombrinck KW Drew AF Grimes TS Kiser JH Degen JL et al . Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. (2000) 96:3302–9. doi: 10.1182/blood.V96.10.3302.h8003302_3302_3309

  • CrossRef
  • Google Scholar

• 125

  Wang M Zhang G Zhang Y Cui X Wang S Gao S et al . Fibrinogen alpha chain knockout promotes tumor growth and metastasis through integrin-akt signaling pathway in lung cancer. Mol Cancer Res. (2020) 18:943–54. doi: 10.1158/1541-7786.Mcr-19-1033

  • CrossRef
  • Google Scholar

• 126

  Schneider G Bryndza E Poniewierska-Baran A Serwin K Suszynska M Sellers ZP et al . Evidence that vitronectin is a potent migration-enhancing factor for cancer cells chaperoned by fibrinogen: A novel view of the metastasis of cancer cells to low-fibrinogen lymphatics and body cavities. Oncotarget. (2016) 7:69829–43. doi: 10.18632/oncotarget.12003

  • CrossRef
  • Google Scholar

• 127

  Qian X Cai J Qi Q Han J Zhu X Xia R et al . Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the pten/akt/mtor pathway. Heliyon. (2023) 9:e16696. doi: 10.1016/j.heliyon.2023.e16696

  • CrossRef
  • Google Scholar

• 128

  Westra J Bijzet J Doornbos-van der Meer B van Rijswijk MH Limburg PC . Differential influence of P38 mitogen activated protein kinase (Mapk) inhibition on acute phase protein synthesis in human hepatoma cell lines. Ann Rheum Dis. (2006) 65:929–35. doi: 10.1136/ard.2005.043232

  • CrossRef
  • Google Scholar

• 129

  Chen L Zhang C Xue R Liu M Bai J Bao J et al . Deep whole-genome analysis of 494 hepatocellular carcinomas. Nature. (2024) 627(8004):586–93. doi: 10.1038/s41586-024-07054-3

  • CrossRef
  • Google Scholar

• 130

  Li P Xiao L Li YY Chen X Xiao CX Liu JJ et al . Fibrinogen alpha chain acts as a hbsag binding protein and their interaction promotes hepg2 cell apoptosis. Curr Proteomics. (2014) 11(1). doi: 10.2174/1570164611666140412003740

  • CrossRef
  • Google Scholar

• 131

  Jiang C Li Y Li Y Liu L Wang XA Wu W et al . Fibrinogen promotes gallbladder cancer cell metastasis and extravasation by inducing icam1 expression. Med Oncol. (2022) 40:10. doi: 10.1007/s12032-022-01874-x

  • CrossRef
  • Google Scholar

• 132

  Shu YJ Weng H Bao RF Wu XS Ding Q Cao Y et al . Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: A retrospective and in vitro study. BMC Cancer. (2014) 14:566. doi: 10.1186/1471-2407-14-566

  • CrossRef
  • Google Scholar

• 133

  Li M Wang J Wang C Xia L Xu J Xie X et al . Microenvironment remodeled by tumor and stromal cells elevates fibroblast-derived col1a1 and facilitates ovarian cancer metastasis. Exp Cell Res. (2020) 394:112153. doi: 10.1016/j.yexcr.2020.112153

  • CrossRef
  • Google Scholar

• 134

  Li C Qiu S Liu X Guo F Zhai J Li Z et al . Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-ddr signaling. Signal Transduct Target Ther. (2023) 8:247. doi: 10.1038/s41392-023-01453-0

  • CrossRef
  • Google Scholar

• 135

  Lapitz A Azkargorta M Milkiewicz P Olaizola P Zhuravleva E Grimsrud MM et al . Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. J Hepatol. (2023) 79:93–108. doi: 10.1016/j.jhep.2023.02.027

  • CrossRef
  • Google Scholar

• 136

  Chu HW Chang KP Hsu CW Chang IY Liu HP Chen YT et al . Identification of salivary biomarkers for oral cancer detection with untargeted and targeted quantitative proteomics approaches. Mol Cell Proteomics. (2019) 18:1796–806. doi: 10.1074/mcp.RA119.001530

  • CrossRef
  • Google Scholar

• 137

  Zhong J . Fibrinogen-to-albumin ratios are related to mortality in patients with secondary Malignant neoplasm of bone and bone marrow. Heliyon. (2023) 9:e18797. doi: 10.1016/j.heliyon.2023.e18797

  • CrossRef
  • Google Scholar

• 138

  Li B Deng H Lei B Chen L Zhang X Sha D . The prognostic value of fibrinogen to albumin ratio in Malignant tumor patients: A meta-analysis. Front Oncol. (2022) 12:985377. doi: 10.3389/fonc.2022.985377

  • CrossRef
  • Google Scholar

• 139

  Marchetti C Romito A Musella A Santo G Palaia I Perniola G et al . Combined plasma fibrinogen and neutrophil lymphocyte ratio in ovarian cancer prognosis may play a role? Int J Gynecol Cancer. (2018) 28:939–44. doi: 10.1097/igc.0000000000001233

  • CrossRef
  • Google Scholar